Hyperspectral imaging and robust statistics in non-melanoma skin cancer analysis.
Journal
Biomedical optics express
ISSN: 2156-7085
Titre abrégé: Biomed Opt Express
Pays: United States
ID NLM: 101540630
Informations de publication
Date de publication:
01 Aug 2021
01 Aug 2021
Historique:
received:
19
04
2021
revised:
21
06
2021
accepted:
28
06
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Non-Melanoma skin cancer is one of the most frequent types of cancer. Early detection is encouraged so as to ensure the best treatment, Hyperspectral imaging is a promising technique for non-invasive inspection of skin lesions, however, the optimal wavelengths for these purposes are yet to be conclusively determined. A visible-near infrared hyperspectral camera with an ad-hoc built platform was used for image acquisition in the present study. Robust statistical techniques were used to conclude an optimal range between 573.45 and 779.88 nm to distinguish between healthy and non-healthy skin. Wavelengths between 429.16 and 520.17 nm were additionally found to be optimal for the differentiation between cancer types.
Identifiants
pubmed: 34513245
doi: 10.1364/BOE.428143
pii: 428143
pmc: PMC8407807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5107-5127Informations de copyright
© 2021 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest related to this article
Références
Biomed Opt Express. 2018 Nov 15;9(12):6283-6301
pubmed: 31065429
Lancet. 2010 Feb 20;375(9715):673-85
pubmed: 20171403
Head Neck. 2016 Jun;38(6):824-31
pubmed: 25546817
Lasers Surg Med. 2019 Mar;51(3):214-222
pubmed: 30653684
Phys Med Biol. 2013 Jun 7;58(11):R37-61
pubmed: 23666068
Cancers (Basel). 2019 Sep 14;11(9):
pubmed: 31540063
R Soc Open Sci. 2017 Dec 6;4(12):171085
pubmed: 29308247
J Clin Med. 2020 Sep 04;9(9):
pubmed: 32899768
JAMA Oncol. 2017 Jul 1;3(7):998-1000
pubmed: 27930769
PLoS One. 2020 Oct 8;15(10):e0240328
pubmed: 33031413
Sci Rep. 2021 May 13;11(1):10209
pubmed: 33986378
Oncol Rep. 2006 Jul;16(1):197-202
pubmed: 16786146
Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:33-6
pubmed: 24109617
Exp Dermatol. 2017 Jul;26(7):615-618
pubmed: 27783441
J Invest Dermatol. 2014 Jan;134(1):43-50
pubmed: 23877569
Int J Paleopathol. 2018 Jun;21:64-76
pubmed: 29776878
Br J Dermatol. 2008 Sep;159(3):669-76
pubmed: 18616769
Cancer Res Treat. 2018 Jul;50(3):729-737
pubmed: 28707459
Arch Dermatol. 2008 Apr;144(4):476-82
pubmed: 18427041
J Invest Dermatol. 2017 Sep;137(9):1860-1867
pubmed: 28487088
Lancet Oncol. 2002 Mar;3(3):159-65
pubmed: 11902502
J Am Acad Dermatol. 2017 Jan;76(1):129-139.e10
pubmed: 27707591
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6
pubmed: 11966724
J Clin Med. 2020 Jun 01;9(6):
pubmed: 32492848
PLoS One. 2018 Apr 24;13(4):e0196004
pubmed: 29689076
Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16
pubmed: 27087480
Sensors (Basel). 2019 Apr 09;19(7):
pubmed: 30970657
Br J Dermatol. 2002 Sep;147(3):481-6
pubmed: 12207587
PLoS One. 2014 Mar 17;9(3):e90924
pubmed: 24637948
J Biomed Opt. 2006 Nov-Dec;11(6):064026
pubmed: 17212549
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
J Biomed Opt. 2014;19(11):117003
pubmed: 25375350
Psychooncology. 2017 Aug;26(8):1070-1079
pubmed: 27643482
Dermatol Surg. 2007 Aug;33(8):885-99
pubmed: 17661931
J Biomed Opt. 2011 Jun;16(6):060502
pubmed: 21721796
Br J Dermatol. 2016 Jun;174(6):1258-65
pubmed: 26872563
J Am Acad Dermatol. 2013 Jun;68(6):957-66
pubmed: 23375456
Arch Dermatol. 2010 Mar;146(3):283-7
pubmed: 20231499
Am J Prev Med. 2015 Feb;48(2):183-187
pubmed: 25442229
Dermatol Surg. 2018 Feb;44(2):193-197
pubmed: 28857942
J Biophotonics. 2020 Jan;13(1):e201960080
pubmed: 31602799
Lasers Surg Med. 2020 Jul;52(6):496-502
pubmed: 31522461
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):71-78
pubmed: 29846972